• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Antiestrogen chemoprevention of breast cancer: critical issues and research.

作者信息

Love R R

机构信息

Cancer Prevention and Breast Cancer Program, University of Wisconsin Clinical Cancer Center, Madison.

出版信息

Prev Med. 1991 Jan;20(1):64-78. doi: 10.1016/0091-7435(91)90007-q.

DOI:10.1016/0091-7435(91)90007-q
PMID:2008428
Abstract

Estrogenic hormones play critical roles in many aspects of women's health. Therefore, the impact of any hormonal manipulation must be carefully considered. While the evidence is good that chemoprevention, or more accurately chemosuppression, of breast cancer with tamoxifen is possible, further data are needed to support the case that hormone replacement with tamoxifen in healthy postmenopausal women would provide overall health benefits. Specifically, further data are needed regarding the biological effects of tamoxifen on risk factors for cardiovascular disease, on bone, on the liver, on the uterus, and on the coagulation system. Frequency, severity, and predictors for vasomotor, gynecologic, and depressant side effects also need to be well described. These data will allow rigorous cost-effectiveness analysis of hormone replacement therapies with tamoxifen and estrogen, as well as an analysis of the cost effectiveness of a clinical trial to prove definitively critical health benefits.

摘要

相似文献

1
Antiestrogen chemoprevention of breast cancer: critical issues and research.
Prev Med. 1991 Jan;20(1):64-78. doi: 10.1016/0091-7435(91)90007-q.
2
[Hormone replacement therapy in menopausal women previously treated for breast cancer].[曾接受乳腺癌治疗的绝经后女性的激素替代疗法]
Presse Med. 1996 Feb 3;25(4):141-4.
3
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.选择性雌激素受体调节与降低乳腺癌、骨质疏松症和冠心病风险
J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. doi: 10.1093/jnci/93.19.1449.
4
Tamoxifen prophylaxis in breast cancer.他莫昔芬用于乳腺癌的预防
Oncology (Williston Park). 1992 Jul;6(7):33-8; discussion 38-40, 43.
5
Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.特邀评论:激素治疗的风险与益处——妇女健康倡议研究结果及绝经后雌激素时机假说
Am J Epidemiol. 2009 Jul 1;170(1):24-8. doi: 10.1093/aje/kwp113. Epub 2009 May 25.
6
[Menopause, hormonal replacement therapy, and coronary disease].
Arq Bras Cardiol. 1995 Apr;64(4):355-8.
7
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.美国临床肿瘤学会关于降低乳腺癌风险策略的技术评估:他莫昔芬和雷洛昔芬。
J Clin Oncol. 1999 Jun;17(6):1939-55. doi: 10.1200/JCO.1999.17.6.1939.
8
Risks and benefits associated with hormonal and surgical therapies for healthy midlife women.健康中年女性激素治疗和手术治疗的风险与益处。
West J Nurs Res. 1994 Oct;16(5):507-23. doi: 10.1177/019394599401600505.
9
Menopause and hormone replacement therapy.绝经与激素替代疗法。
Clin Geriatr Med. 1993 Feb;9(1):33-55.
10
Hormone replacement therapy and the risk of breast cancer: assessment of therapy acceptance in a cohort of previously treated breast cancer patients.激素替代疗法与乳腺癌风险:对一组既往接受过治疗的乳腺癌患者的治疗接受度评估
Rev Hosp Clin Fac Med Sao Paulo. 2003 Mar-Apr;58(2):91-6. doi: 10.1590/s0041-87812003000200006. Epub 2003 Jun 25.

引用本文的文献

1
Tamoxifen and cancer of the endometrium.他莫昔芬与子宫内膜癌
CMAJ. 1993 Jun 15;148(12):2113-4.
2
Accrual to the Breast Cancer Prevention Trial by participating Community Clinical Oncology Programs: a panel data analysis.参与社区临床肿瘤项目的乳腺癌预防试验的应计情况:面板数据分析
Breast Cancer Res Treat. 1995 Jul;35(1):43-50. doi: 10.1007/BF00694744.